Subscribe To

Price Alert Latest News Economic Calendar News

AGIO / Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know

The consensus price target hints at a 42.5% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Read More

Demo Live Account See Partner Details

Content Topics

Wall

Street

Analysts

Predict

42

46 Upside

Agios

42 46

Pharmaceuticals

agio

Here s

Should

Stock

AGIO

Posted: May 9 2023, 11:27

Author Name: Zacks Investment Research

AGIO News

By Zacks Investment Research
November 3, 2023

Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales

Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.

By GlobeNewsWire
November 2, 2023

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease

By Seeking Alpha
August 17, 2023

Agios Pharmaceuticals: Positive Phase 2 Results In Sickle Cell Study

Agios Pharmaceuticals is a biotech company focused on developing medicines for cancer and rare genetic diseases. The company's financials show growth,

By Zacks Investment Research
August 4, 2023

Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line

Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.

By Seeking Alpha
August 3, 2023

Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2023 Results Conference Call August 3, 2023 8:00 AM ET Company Participants Christopher Taylor - Vice Pr

By Zacks Investment Research
July 17, 2023

Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Agios Pharmaceuticals (AGIO). While the effectivenes

By Zacks Investment Research
June 28, 2023

Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?

Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

By Zacks Investment Research
June 27, 2023

Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint

Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed wi

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.